Halofuginone hydrobromide - CAS 64924-67-0
Category: APIs
Molecular Formula:
Molecular Weight:
Halofuginone hydrobromide is a salt form of Halofuginone, which is a coccidiostat used in veterinary medicine.
DL-trans-7-Bromo-6-chloro-3-[3-(3-hydroxypiperidin-2-yl)-2-oxopropyl]-3H-quinazolin-4-one hydrobromide
1.Potential therapeutical effects of topical halofuginone hydrobromide in keloid management.
Lista S, Emanuele E. Med Hypotheses. 2007;69(3):707. Epub 2007 Feb 28.
2.Therapeutic efficacy of halofuginone and spiramycin treatment against Cryptosporidium serpentis (Apicomplexa: Cryptosporidiidae) infections in captive snakes.
Graczyk TK1, Cranfield MR, Hill SL. Parasitol Res. 1996;82(2):143-8.
The therapeutic effect of halofuginone hydrobromide (Steronol) and spiramycin solubilized (Spirasol) applied to clinical Cryptosporidium serpentis infections in captive snakes was investigated. Pathological changes induced by C. serpentis were typical for snake cryptosporidiosis. Spiramycin induced no significant change in the pattern of shedding of fecal Cryptosporidium oocysts; biopsies and necropsies revealed cryptosporidiosis in gastric mucosa of all spiramycin-treated animals. In all, 8 of 21 (38%) halofuginone-treated snakes stopped shedding C. serpentis oocysts; examination of gastric tissue of 6 of these 8 animals revealed cryptosporidiosis in 2 snakes. Hepatotoxic and nephrotoxic pathological changes induced by halofuginone included focal or multifocal, severe, acute liver necrosis; severe liver hemosiderosis; and bilateral, severe, acute diffuse cortical and tubular necrosis and iron deposition. Postprandial regurgitation associated with midbody swelling, observed in 4 halofuginone-treated and 2 spiramycin-treated snakes at 15 and 21 weeks after drug withdrawal, did not coincide with oocyst-positive feces.
3.Efficacy of topical halofuginone in myringotomy patency.
Ozdemir T1, Cincik H, Dogru S, Cekin IE, Ulubil SA, Gungor A. Eur Arch Otorhinolaryngol. 2010 Nov;267(11):1701-4. doi: 10.1007/s00405-010-1306-z. Epub 2010 Jun 24.
The objective of the study is to determine whether topical halofuginone (HF) application has an impact on prolonging the time for healing of myringotomy incision, and to investigate histopathologic effects of HF on tympanic membrane (TM) in rat model. Forty rats with normal eardrums were involved in this study. The study group and control group consisted of 30 and 10 rats, respectively. A posterior incision 1 mm in diameter was made on healthy eardrums of the rats. Following incision, gelfoam soaked with HF hydrobromide of 30 mg/dl was applied on the perforation in study group, whereas gelfoam soaked with isotonic saline was applied on the perforation in control group. On days 1, 3, 7, 10, 14, 18, 21, 24, 27, and 30, otoendoscopic evaluation of eardrums under general anesthesia was conducted and perforations were screened. A rat of each group was killed in control days and TMs were dissected to evaluate histopathological changes. The average times for patency of perforation in study and control groups were 21.
4.Field study of the efficacy of halofuginone and decoquinate in the treatment of cryptosporidiosis in veal calves.
Lallemand M1, Villeneuve A, Belda J, Dubreuil P. Vet Rec. 2006 Nov 11;159(20):672-6.
Ninety, seven- to 10-day-old calves were allocated to three groups of 30 and treated daily for seven days with either 100 microg/kg halofuginone hydrobromide or 2.5 mg/kg decoquinate orally or left untreated as controls. The levels of diarrhoea and dehydration were monitored daily for 28 days from the first day of treatment (day 0) and samples of faeces were collected on days 0, 7, 14, 21 and 28, to quantify the excretion of Cryptosporidium parvum oocysts. The calves were weighed on days 3 and 28. The treatments had no effect on the levels of diarrhoea or dehydration, the proportions of diarrhoeic calves or the proportions of calves shedding oocysts. However, unlike decoquinate, halofuginone significantly reduced the excretion of oocysts on day 7 (P<0.0001), and decoquinate increased the average daily weight gain of the calves (P=0.049).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 5534-02-1 Betamethasone-17-butyrate-21-propionate

(CAS: 5534-02-1)

Betamethasone-17-butyrate-21-propionate is a topical corticosteroid that is potent to treat inflammatory skin diseases.

CAS 58-85-5 D-Biotin

(CAS: 58-85-5)

CAS 70024-40-7 Terazosin HCL

Terazosin HCL
(CAS: 70024-40-7)

CAS 91421-42-0 Rubitecan

(CAS: 91421-42-0)

CAS 138926-19-9 Ibandronate Sodium

Ibandronate Sodium
(CAS: 138926-19-9)

Ibandronate Sodium is a salt form of Ibandronate, a medication used for the treatment of osteoporosis.

CAS 131707-23-8 Arbidol Hydrochloride

Arbidol Hydrochloride
(CAS: 131707-23-8)

CAS 668270-12-0 Linagliptin

(CAS: 668270-12-0)

Chemical Structure

CAS 64924-67-0 Halofuginone hydrobromide

Quick Inquiry

Verification code

Featured Items